CD8 T cells, which have a crucial role in immunity to infection and cancer, are maintained in constant numbers, but on antigen stimulation undergo a developmental program characterized by distinct phases encompassing the expansion and then contraction of antigen-specific effector (T E ) populations, followed by the persistence of long-lived memory (T M ) cells 1,2 . Although this predictable pattern of CD8 T-cell responses is well established, the underlying cellular mechanisms regulating the transition to T M cells remain undefined 1,2 . Here we show that tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6), an adaptor protein in the TNF-receptor and interleukin-1R/Toll-like receptor superfamily, regulates CD8 T M -cell development after infection by modulating fatty acid metabolism. We show that mice with a T-cell-specific deletion of TRAF6 mount robust CD8 T E -cell responses, but have a profound defect in their ability to generate T M cells that is characterized by the disappearance of antigen-specific cells in the weeks after primary immunization. Microarray analyses revealed that TRAF6-deficient CD8 T cells exhibit altered expression of genes that regulate fatty acid metabolism. Consistent with this, activated CD8 T cells lacking TRAF6 display defective AMP-activated kinase activation and mitochondrial fatty acid oxidation (FAO) in response to growth factor withdrawal. Administration of the anti-diabetic drug metformin restored FAO and CD8 T M -cell generation in the absence of TRAF6. This treatment also increased CD8 T M cells in wild-type mice, and consequently was able to considerably improve the efficacy of an experimental anti-cancer vaccine.
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A prevailing paradigm in immunology is that antigenic signal strength drives progressive T-cell differentiation 3 . To investigate this model regarding T M cells, we studied CD8 T-cell responses to bacterial infection in mice with a T-cell-specific deletion of TRAF6 (TRAF6-DT), a negative regulator of antigen-specific T-cell activation 4 . Despite having fewer total CD8 T cells (Supplementary Fig. 1 ), TRAF6-DT mice mounted normal ovalbumin (OVA)-specific T Ecell responses to attenuated Listeria monocytogenes expressing OVA (LmOVA; Fig. 1a and Supplementary Fig. 2 ). To examine CD8 T M cells in TRAF6-DT mice, we immunized with LmOVA and measured OVA-specific cells 60 days post-infection. Although OVA-specific T E -cell responses were intact, CD8 T M -cell generation in TRAF6-DT mice was severely compromised (Fig. 1b and Supplementary  Fig. 3 ), even with tenfold higher or lower immunizing doses (not shown). In mice lacking cbl-b 5 , a different negative regulator of antigen-specific T-cell activation, T M cells developed normally ( Supplementary Fig. 4 ), indicating that failure of T M -cell generation in TRAF6-DT mice cannot be entirely explained by loss of a negative regulator. A hallmark of T M cells is the ability to mount accelerated recall responses to challenge infection. To confirm the impaired generation of CD8 T M cells in TRAF6-DT mice, we challenged previously immunized control and TRAF6-DT mice with LmOVA and measured OVA-specific cells 7 days later. TRAF6-DT mice failed to respond robustly to re-infection, indicating that T M cells may not have been generated and that the smaller OVA-specific population present in TRAF6-DT mice was a new primary response (Fig. 1c) . To determine whether TRAF6-DT mice generate T M cells, we transferred equal numbers of OVA-specific cells from previously immunized control and TRAF6-DT mice 28 days post-infection, at which time a small population of OVA-specific cells appeared to be present ( Supplementary Fig. 3) , and compared functionality on a per cell basis in response to challenge. We reasoned that naive donor cells transferred into immune-competent animals would not respond to infection because they would be vigorously outcompeted by endogenous naive cells, and only T M donor cells would mount accelerated recall responses that could outcompete endogenous naive cells. At day 7 post-challenge, donor-derived OVA-specific secondary T E cells from control mice represented 11% of the engrafted population whereas TRAF6-DT donor cells were undetectable ( Supplementary  Fig. 5 ), demonstrating a severe impairment in CD8 T M -cell development in TRAF6-DT mice.
TRAF6-DT mice accumulate CD4 T cells and develop multi-organ inflammatory disease 4 . Because CD4 T cells can influence CD8 T-cell responses [6] [7] [8] we wanted to rule out effects from the TRAF6-deficient CD4 T-cell compartment. To determine whether defective CD8 T Mcell generation in TRAF6-DT mice was intrinsic to CD8 T cells, we crossed TRAF6-DT mice with major-histocompatibility-complexclass-I-restricted OVA-specific T-cell-receptor-transgenic OT-I mice. Because OT-I mice lack CD4 T cells, generation of OTI-TRAF6-DT mice allowed us to assay a pure population of uniformly naive TRAF6-deficient CD8 T cells (Supplementary Figs 6-8 ). We transferred OTI-TRAF6-wild type (WT) and OTI-TRAF6-DT cells into congenic recipients, which possess a normal CD4 T-cell compartment, and then immunized with LmOVA ( Fig. 2a) . By transferring only small numbers of transgenic cells we could measure endogenous OVA-specific cells at the same time as the engrafted donor response, allowing us to assume that most donor cells were activated 9 . In addition, following T-cell responses by serially bleeding allowed us to compare the kinetics of responding CD8 T cells within individual animals. Although both OTI-TRAF6-WT and OTI-TRAF6-DT donor cells mounted strong T E -cell responses (days 4-6), OTI-TRAF6-DT cells were not maintained during contraction (days 10-21) and were undetectable by 3 weeks post-infection (Fig. 2b, c and Supplementary Fig. 9 ). Donor T E cells from both genotypes exhibited similar expression of classical activation markers after primary immunization (Supplementary Figs 10 and 11) ; however, consistent with published data regarding killer cell lectin-like receptor 1 (KLRG1) as a marker for short-lived T E cells that do not form T M cells, a greater percentage of the OTI-TRAF6-DT T E -cell population expressed higher levels of KLRG1 ( Supplementary Fig.  12 ) 10 . After challenge infection, only donor OTI-TRAF6-WT T M cells responded robustly (Fig. 2b, c and Supplementary Fig. 9 ). These results demonstrate that, although TRAF6 is dispensable for CD8 T E -cell responses, TRAF6 signalling within CD8 T cells is crucial to T M -cell generation.
Antigen-specific CD8 T cells responding to infection are not a homogenous population, but consist of small numbers of T M -cell precursors that express interleukin 7 receptor (IL7Ra; ref. 11). In conjunction with this idea, numerous studies have delineated roles for the c c cytokines IL7 and IL15 as critical factors for CD8 T-cell homeostasis and T M -cell development [12] [13] [14] [15] . Impaired c c cytokine signalling in TRAF6-deficient CD8 T cells could explain the defect in their ability to form T M cells. We tested the ability of CD8 T E cells to respond to IL15 and found that both OTI-TRAF6-WT and OTI-TRAF6-DT cells exhibit similar responsiveness to this cytokine ( Supplementary Figs 13 and 14) . To be sure that the lack of T M -cell development by TRAF-6-deficient CD8 T cells is not secondary to a defect in survival, and to investigate further a possible defect in c c cytokine signalling, we crossed OTI-TRAF6-DT mice to mice constitutively expressing an active form of Stat-5 (also known as Stat5b; CASt5) 16 , a critical signalling molecule downstream of the c c cytokine receptor 16 . CD8 T cells expressing CA-St5 show augmented survival, proliferation and B-cell leukemia/lymphoma 2 (Bcl2) expression 17 , and CA-St5 mice exhibit selective expansion of memory-like CD8 T cells 16 . We transferred CA-St5-OTI-TRAF6-WT and CA-St5-OTI-TRAF6-DT cells into congenic mice, immunized, and followed the donor and host OVA-specific responses ( Fig. 2d and Supplementary  Fig. 15 ). Contraction of CA-St5-OTI-TRAF6-WT populations was reduced compared to control OT-I populations (Fig. 2c, d) . Surprisingly, however, CA-St5-OTI-TRAF6-DT cells were not rescued from contracting to undetectable levels 3 weeks post-infection (Fig. 2d and Supplementary Fig. 15) . Supplementary Fig. 16 ), indicating that the severe contraction exhibited by the TRAF6-deficient OT-I population (Fig. 2c, d and Supplementary Fig. 15 ) and the ensuing lack of T Mcell development is not secondary to a general survival defect. Animals primed with the challenge dose of bacteria 3 weeks post-transfer showed no differences in the T E -cell response between the genotypes (Fig. 2e and Supplementary Fig. 15 ), indicating that the loss of TRAF6-deficient CD8 T cells is exaggerated in response to signals after infection, and not simply due to defects in homeostatic signals after transfer.
We used a systems biology approach to identify unique gene expression signatures between OTI-TRAF6-WT and OTI-TRAF6-DT CD8 T cells that could account for their differences in survival after infection. We performed microarray analyses for both genotypes 6 and 10 days post-transfer and infection ( Supplementary  Fig. 17 ). Owing to similar survival rates between OTI-TRAF6-WT and OTI-TRAF6-DT CD8 T cells during the peak of the T E -cell response, but striking differences in survival during contraction, we reasoned that expression of genes related to survival might begin to diverge between genotypes at day 10 post-infection. We used the NIAID DAVID website (http://david.abcc.ncifcrf.gov) to look for pathways in the KEGG database that have significant overlaps with differentially expressed genes in our microarray experiment. We discovered that TRAF6-deficient cells from day 10 post-infection displayed defects in the expression of genes that function in several metabolic pathways, including fatty acid metabolism (Fig. 3a) .
FAO is an important survival pathway in metabolically stressed cells 18 and the removal of signals associated with infection, such as growth factor cytokines including IL2, induces metabolic stress in haematopoietic cells 19, 20 . Therefore, we tested the ability of OTI-TRAF6-WT and OTI-TRAF6-DT CD8 T cells to oxidize fatty acids after withdrawal of the pro-proliferative growth factor cytokine IL2 in vitro. After IL2 withdrawal, only control OTI-TRAF6-WT CD8 T cells increased FAO to a high degree (Fig. 3b) . Consistent with normal activation (Supplementary Fig. 18 ), activated control and TRAF6-deficient CD8 T cells increased glycolysis in response to IL2 (data not shown). Also, TRAF6-deficient CD8 T cells displayed normal upregulation of FAO in response to glucose withdrawal, indicating that cells are not completely unfit in the absence of TRAF6, but rather their inability to regulate catabolic fatty acid metabolism is due to the lack of a specific signal from growth factor (Supplementary Fig. 19 ). Importantly, although transgenic expression of CA-St5 did enhance T-cell survival after infection ( Supplementary Fig. 16 ), it did not rescue the defect in FAO in TRAF6-deficient cells after growth factor withdrawal ( Supplementary Fig. 20 ), indicating that FAO defects are not secondary to survival defects.
Proliferating T cells use glycolytic metabolism rather than FAO for energy generation [21] [22] [23] , and growth factors enable this bias 24 . In the absence of glucose, cells can survive in part by ceasing proliferation and switching to catabolic metabolism like FAO and autophagy 18, 20 . OTI-TRAF6-DT CD8 T cells were notably less capable of effecting this metabolic switch than OTI-TRAF6-WT CD8 T cells after IL2 withdrawal (Fig. 3c) . This indicated that TRAF6-deficient CD8 T cells responding to infection are unable to survive contraction and persist as long-lived T M cells due to an inability to properly engage pathways of FAO when growth factors such as IL2 become limiting after the peak of the immune response.
AMP-activated kinase (AMPK) and Akt are central regulators of FAO and glycolyis, respectively 23 . Consistent with reduced FAO, TRAF6-deficient CD8 T cells have lower active AMPK levels after IL2 withdrawal (Fig. 3d) . To investigate whether AMPK defects could underlie decreased FAO in TRAF6-deficient CD8 T cells, we measured the effect of the anti-diabetic drug metformin, which promotes AMPK activation 25 , on FAO after IL2 withdrawal. Metformin increased AMPK activation (Fig. 3d) and rescued FAO in TRAF6-deficient CD8 T cells (Fig. 3e) . In contrast, FAO in TRAF6-deficient cells was unaffected by the Akt inhibitor triciribine (Fig. 3e) , indicating that Akt may not regulate this metabolic pathway. These data support that FAO initiation after the peak of infection, accompanied by the reduction in T-cell survival signals, underlies T M -cell development, and that commitment to this metabolic pathway is affected when TRAF6 is absent. In such a case, stimulating FAO in TRAF6-deficient CD8 T cells would rescue the observed defects and promote T M cells. Consistent with this hypothesis, OTI-TRAF6-DT CD8 T cells had lower levels of active AMPK at the peak of the T E -cell response (Fig. 3f) .
To explore whether inducing FAO in vivo would rescue the observed defects in TRAF6-deficient CD8 T cells and promote T M cells, we administered metformin daily after T-cell transfer and infection. Remarkably, metformin promoted survival not only of OTI-TRAF6-DT CD8 T cells throughout contraction but also of endogenous OVA-specific cells, resulting in enhanced T M cells with the capacity to respond to re-infection ( Fig. 4a and Supplementary  Fig. 21 ). Metformin also promoted OTI-TRAF6-WT CD8 T-cell survival (Fig. 4b) . Treatment with a second FAO-inducing drug [26] [27] [28] , the mTOR (mammalian target of rapamycin, also known as FRAP1) inhibitor rapamycin, resulted in markedly increased T M -cell development and ensuing recall response for both OTI-TRAF6-DT and OTI-TRAF6-WT CD8 T cells (Fig. 4a, b and Supplementary Fig.  21 ). Together these data strongly point towards the commitment to FAO as a key requirement for T M -cell development, and the pharmacological modulation of this metabolic pathway as a potential target for vaccine design.
Promoting CD8 T M -cell development is a major goal of vaccination. Our data showing increased CD8 T M cells for donor OT-I and endogenous OVA-specific cells after metformin treatment indicated that commitment to FAO is generally important for CD8 T M -cell development, and not only in settings of TRAF6-deficiency. This led us to the idea that pharmacological modulation of T-cell metabolism could enhance vaccine efficacy. To test this we used an experimental vaccine against an aggressive tumour 29 . We immunized control mice with LmOVA and then began daily injections of PBS or metformin after the peak of the T E -cell response. After 3 weeks, drug treatment ceased and mice were inoculated with EL4-OVA tumour cells (Fig. 4c) . Metformin was administered after T E -cell expansion to avoid the possibility of altering the T E -cell response. To rule out direct effects of metformin on tumour growth, treatment was stopped 24 h before tumour injection. After EL4-OVA inoculation, 6 out of 9 metformin-treated mice survived .33 days compared to only 1 out of 8 PBS-treated mice (Fig. 4c) . This increase in survival after metformin treatment correlated with an increase in T M cells before tumour inoculation ( Supplementary Fig. 22 ), indicating that metformin treatment enhanced T M -cell generation resulting in greater protective anti-tumour immunity.
Proliferating T cells use glucose as their main energy source and suppress fatty acid metabolism, whereas quiescent cells (that is, naive and T M ) break down fatty acids, amino acids and glucose interchangeably for energy 23 . As such, proliferating T E cells display an anabolic signature typified by increased glycolytic metabolism, whereas T M cells display a catabolic signature. This implies that during contraction there is an active conversion of cellular energy metabolism to generate T M cells. Current models suggest that during contraction T cells compete for growth factors such as IL2, and we speculate that as these growth factors become limiting cells become stressed and undergo a metabolic transformation essential for T M -cell generation. We propose a model in which TRAF6 has a critical role after infection by regulating a metabolic switch in CD8 T cells that promotes survival and development into long-lived T M cells.
Investigating the role of TRAF6 in T M -cell development led us to the surprising finding that energy metabolism can be pharmacologically manipulated during an immune response to promote CD8 T Mcell generation and protective immunity. Although the exact mechanism of metformin-mediated CD8 T M -cell enhancement remains unclear, our work indicates that metabolism-altering drugs hold promise as immunotherapeutics and command further study as modulators of T-cell responses. Metformin has been shown to inhibit tumour progression 25, 30 , although given our results it is unclear how metformin-regulated changes in T M cells contribute to its antitumour properties. Our findings highlight a critical link between metabolic transitions and cell fate determination, and may have important implications for therapeutic and prophylactic vaccine development. CD4-cre(1) (TRAF6-DT) were bred in-house (backcrossed more than ten generations to C57BL/6) and have been previously described 4 . C57BL/6 (WT) and OT-I transgenic mice were purchased from The Jackson Laboratory. OT-I mice were bred to TRAF6 2) were transferred into CD45.1 recipients and immunized with LmOVA. Eight days post-infection, mice were injected daily with PBS (n 5 7-9 per group), metformin (n 5 7-9 per group) or rapamycin (n 5 5 per group) for 3 weeks and were then challenged with LmOVA. OVA-specific responses of host and donor cells in the blood were measured 5 days post-challenge. Dot plot numbers reflect the percentages of total CD8 T cells that are host-(left) or donor-(right) derived (OVA-specific). Bar graphs represent the percentage of CD8 T cells that are donor-derived (means and standard error). *P values (comparing to PBS) are 0.015 (Met) and 0.000038 (Rap) (a), and 0.0373 (Met) and 0.00028 (Rap) (b). c, C57BL/6 mice were immunized and daily injections of metformin or PBS began 7 days post-infection. Three weeks later, treatments ceased and mice were inoculated with EL4-OVA tumours. Tumours became palpable by 18 days post-inoculation and mice were killed when tumours reached 2 cm. The graph reflects percentage survival (n 5 9, metformin; n 5 8, PBS).
METHODS SUMMARY
CFU for secondary immunizations. Acute LmOVA infections are resolved and bacteria are cleared by day 7 in all mice. All P values were calculated using unpaired two-tailed Student's t-test.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
